MLD-41

MLD-41, also known as 1-methyl-LSD, is a psychedelic drug of the lysergamide family related to lysergic acid diethylamide (LSD).^[1]^[2] It has about 33% of the psychoactive potency of LSD.^[1]^[2] It has been studied with regard to cross-tolerance with LSD.^[3] Extensive metabolism of other 1-methylated lysergamides to their secondary amine derivatives, for instance methysergide (1-methylmethylergometrine) conversion into methylergometrine, has been observed.^[4]^[5]

Other namesMLD-41; N1-Methyl-Lysergic Acid Diethylamide; 1-Methyl-LSD; 1-Methyl-N,N-Diethyllysergamide; Methyl-LSD

Routes of
administrationOral^[1]^[2]

Drug classSerotonergic psychedelic; Hallucinogen

CAS Number

4238-85-1^Y

Quick facts Clinical data, Other names ...

MLD-41
Clinical data


Other names	MLD-41; N1-Methyl-Lysergic Acid Diethylamide; 1-Methyl-LSD; 1-Methyl-N,N-Diethyllysergamide; Methyl-LSD
Routes of administration	Oral^[1]^[2]
Drug class	Serotonergic psychedelic; Hallucinogen
Identifiers
IUPAC name (8β)-N,N-Diethyl-1,6-dimethyl-9,10-didehydroergoline-8-carboxamide
CAS Number	4238-85-1^Y
PubChem CID	165200
ChemSpider	144824^Y
CompTox Dashboard (EPA)	DTXSID00895034
Chemical and physical data
Formula	C₂₁H₂₇N₃O
Molar mass	337.467 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES O=C(N(CC)CC)[C@@H]3/C=C2/c4cccc1c4c(cn1C)C[C@H]2N(C3)C
InChI InChI=1S/C21H27N3O/c1-5-24(6-2)21(25)15-10-17-16-8-7-9-18-20(16)14(12-22(18)3)11-19(17)23(4)13-15/h7-10,12,15,19H,5-6,11,13H2,1-4H3/t15-,19-/m1/s1^Y Key:VQZYKSWQIQANKB-DNVCBOLYSA-N^Y
(verify)

Interactions

Society and culture

Legal status

Canada

MLD-41 is not a controlled substance in Canada as of 2025.^[6]

References

[1]
Jacob P, Shulgin AT (1994). "Structure-activity relationships of the classic hallucinogens and their analogs" (PDF). NIDA Res Monogr. 146: 74–91. PMID 8742795. Archived from the original (PDF) on August 5, 2023.
[2]
Hoffer A (1965). "D-Lysergic acid diethylamide (LSD): A review of its present status". Clin Pharmacol Ther. 6: 183–255. doi:10.1002/cpt196562183. PMID 14288188.
[3]
Abramson HA, Rolo A, Sklarofsky B, Stache J (January 1960). "Production of cross-tolerance to psychosis-producing doses of lysergic acid diethylamide and psilocybin". The Journal of Psychology. 49 (1): 151–154. doi:10.1080/00223980.1960.9916396.
[4]
Majrashi M, Ramesh S, Deruiter J, Mulabagal V, Pondugula S, Clark R, Dhanasekaran M (2017). "Multipotent and Poly-therapeutic Fungal Alkaloids of Claviceps purpurea". In Agrawal DC, Tsay HS, Shyur LF, Wu YC, Wang SY (eds.). Medicinal Plants and Fungi: Recent Advances in Research and Development. Medicinal and Aromatic Plants of the World. Vol. 4. pp. 229–252. doi:10.1007/978-981-10-5978-0_8. ISBN 978-981-10-5977-3. ISSN 2352-6831. Metabolites of methysergide also exhibit pharmacological activity. Methylergometrine (one of methysergide's metabolites) is responsible for methysergide's therapeutic effects regarding migraine treatment (Müller-Schweinitzer and Tapparelli 1986). [...] The systemic availability of methysergide after oral administration is only 13%, due to a high degree of first-pass metabolism by N-1 demethylation to methylergometrine. After oral administration, the plasma concentrations of the metabolite are considerably higher than those of the parent drug, and the area under the plasma concentration curve (AUC) for methylergometrine is more than ten times greater than for methysergide.
[5]
Müller-Schweinitzer E, Tapparelli C (March 1986). "Methylergometrine, an active metabolite of methysergide". Cephalalgia: An International Journal of Headache. 6 (1): 35–41. doi:10.1046/j.1468-2982.1986.0601035.x. PMID 3698092. S2CID 5778173.
[6]
"Controlled Drugs and Substances Act". Department of Justice Canada. Retrieved 19 January 2026.

Interactions

Society and culture

Legal status

Canada

See also

References

External links

Related Articles